The economic burden of Chagas disease: A systematic review.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
17
07
2023
accepted:
29
10
2023
revised:
06
12
2023
medline:
7
12
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Chagas disease (CD) is a neglected disease affecting millions worldwide, yet little is known about its economic burden. This systematic review is part of RAISE project, a broader study that aims to estimate the global prevalence, mortality, and health and economic burden attributable to chronic CD and Chronic Chagas cardiomyopathy. The objective of this study was to assess the main costs associated with the treatment of CD in both endemic and non-endemic countries. An electronic search of the Medline, Lilacs, and Embase databases was conducted until 31st, 2022, to identify and select economic studies that evaluated treatment costs of CD. No restrictions on place or language were made. Complete or partial economic analyses were included. Fifteen studies were included, with two-thirds referring to endemic countries. The most commonly investigated cost components were inpatient care, exams, surgeries, consultation, drugs, and pacemakers. However, significant heterogeneity in the estimation methods and presentation of data was observed, highlighting the absence of standardization in the measurement methods and cost components. The most common component analyzed using the same metric was hospitalization. The mean annual hospital cost per patient ranges from $25.47 purchasing power parity US dollars (PPP-USD) to $18,823.74 PPP-USD, and the median value was $324.44 PPP-USD. The lifetime hospital cost per patient varies from $209,44 PPP-USD for general care to $14,351.68 PPP-USD for patients with heart failure. Despite the limitations of the included studies, this study is the first systematic review of the costs of CD treatment. The findings underscore the importance of standardizing the measurement methods and cost components for estimating the economic burden of CD and improving the comparability of cost components magnitude and cost composition analysis. Finally, assessing the economic burden is essential for public policies designed to eliminate CD, given the continued neglect of this disease.
Sections du résumé
BACKGROUND
BACKGROUND
Chagas disease (CD) is a neglected disease affecting millions worldwide, yet little is known about its economic burden. This systematic review is part of RAISE project, a broader study that aims to estimate the global prevalence, mortality, and health and economic burden attributable to chronic CD and Chronic Chagas cardiomyopathy. The objective of this study was to assess the main costs associated with the treatment of CD in both endemic and non-endemic countries.
METHODS
METHODS
An electronic search of the Medline, Lilacs, and Embase databases was conducted until 31st, 2022, to identify and select economic studies that evaluated treatment costs of CD. No restrictions on place or language were made. Complete or partial economic analyses were included.
RESULTS
RESULTS
Fifteen studies were included, with two-thirds referring to endemic countries. The most commonly investigated cost components were inpatient care, exams, surgeries, consultation, drugs, and pacemakers. However, significant heterogeneity in the estimation methods and presentation of data was observed, highlighting the absence of standardization in the measurement methods and cost components. The most common component analyzed using the same metric was hospitalization. The mean annual hospital cost per patient ranges from $25.47 purchasing power parity US dollars (PPP-USD) to $18,823.74 PPP-USD, and the median value was $324.44 PPP-USD. The lifetime hospital cost per patient varies from $209,44 PPP-USD for general care to $14,351.68 PPP-USD for patients with heart failure.
DISCUSSION
CONCLUSIONS
Despite the limitations of the included studies, this study is the first systematic review of the costs of CD treatment. The findings underscore the importance of standardizing the measurement methods and cost components for estimating the economic burden of CD and improving the comparability of cost components magnitude and cost composition analysis. Finally, assessing the economic burden is essential for public policies designed to eliminate CD, given the continued neglect of this disease.
Identifiants
pubmed: 37992061
doi: 10.1371/journal.pntd.0011757
pii: PNTD-D-23-00899
pmc: PMC10699619
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011757Informations de copyright
Copyright: © 2023 Andrade et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2018 Jan 6;391(10115):82-94
pubmed: 28673423
Glob Heart. 2022 Aug 24;17(1):59
pubmed: 36051318
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003710
pubmed: 25884198
Am J Trop Med Hyg. 2005 Nov;73(5):901-10
pubmed: 16282301
Int J Cardiol. 2014 Feb 15;171(3):368-76
pubmed: 24398230
PLoS Negl Trop Dis. 2008;2(11):e336
pubmed: 19015725
Front Public Health. 2019 Jul 02;7:166
pubmed: 31312626
Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43
pubmed: 25671846
Int J Infect Dis. 2020 Feb;91:196-201
pubmed: 31770619
Int J Technol Assess Health Care. 2005 Spring;21(2):240-5
pubmed: 15921065
PLoS One. 2022 Apr 21;17(4):e0266346
pubmed: 35446870
Int J Cardiol. 2013 Oct 3;168(3):2375-80
pubmed: 23465560
Mem Inst Oswaldo Cruz. 1991 Jul-Sep;86(3):285-95
pubmed: 1842419
Expert Rev Anti Infect Ther. 2011 May;9(5):609-20
pubmed: 21609270
PLoS Negl Trop Dis. 2014 Apr 17;8(4):e2776
pubmed: 24743112
Am J Trop Med Hyg. 2017 Nov;97(5):1289-1303
pubmed: 29016289
PLoS Negl Trop Dis. 2009;3(1):e363
pubmed: 19156190
Arch Cardiol Mex. 2002 Apr-Jun;72(2):129-37
pubmed: 12148332
Rev Soc Bras Med Trop. 1996 Mar-Apr;29(2):109-15
pubmed: 8713602
Bol Chil Parasitol. 1998 Jan-Jun;53(1-2):23-6
pubmed: 9830720
Glob Heart. 2020 Mar 30;15(1):26
pubmed: 32489799
Lancet. 2010 Apr 17;375(9723):1388-402
pubmed: 20399979
Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):137-43
pubmed: 9764315
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Pharmacoeconomics. 2011 Aug;29(8):653-71
pubmed: 21604822
Trop Med Infect Dis. 2021 Jan 27;6(1):
pubmed: 33513668
PLoS Negl Trop Dis. 2018 Nov 5;12(11):e0006809
pubmed: 30395603
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Acta Trop. 2015 Aug;148:77-88
pubmed: 25917718
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Nov;39(9):458-470
pubmed: 34736749
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Malar J. 2022 Oct 5;21(1):283
pubmed: 36199078
Rev Soc Bras Med Trop. 2005;38 Suppl 2:108-13
pubmed: 16482828
Glob Heart. 2015 Sep;10(3):139-44
pubmed: 26407508
Expert Rev Cardiovasc Ther. 2015 Dec;13(12):1393-409
pubmed: 26496376
BMC Cardiovasc Disord. 2018 May 2;18(1):74
pubmed: 29716540
J Health Econ. 2008 Mar;27(2):405-26
pubmed: 18222556
Am J Trop Med Hyg. 2018 Jun;98(6):1733-1742
pubmed: 29714163
Lancet Infect Dis. 2013 Apr;13(4):342-8
pubmed: 23395248
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326